接受雄激素剥夺治疗并使用新型雄激素受体信号抑制剂治疗晚期或转移性前列腺癌男性的骨折与跌倒风险:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入23项随机对照试验,评估在标准雄激素剥夺治疗(ADT)基础上加用雄激素受体信号抑制剂(ARSI)对晚期前列腺癌患者骨折和跌倒风险的影响。汇总分析显示,与对照相比,ARSI使骨折风险(RR 2.32,95%CI 2.00-2.71;p<0.01)和跌倒风险(RR 2.22,95%CI 1.81-2.72;p<0.01)显著增加。作者结论认为,在标准ADT基础上加用ARSI显著增加前列腺癌男性的骨折和跌倒风险。
要点
- 与对照相比,ARSI使骨折风险增加(RR 2.32,95%CI 2.00-2.71;p<0.01)。
- 与对照相比,ARSI使跌倒风险增加(RR 2.22,95%CI 1.81-2.72;p<0.01)。
- 转移性激素敏感性前列腺癌亚组中,骨折(RR 2.13,95%CI 1.70-2.67;p<0.01)和跌倒(RR 2.19,95%CI 1.53-3.12;p<0.0001)风险均增加。
核心结论
- 在标准ADT基础上加用ARSI显著增加前列腺癌男性的骨折和跌倒风险。
研究设计与样本
- 系统综述与Meta分析,检索EMBASE、MEDLINE、Cochrane图书馆和卫生技术评估数据库1990年至2023年6月间的随机对照试验,纳入23项研究。
- 骨折结局报告于17项研究(N=18 811),跌倒结局报告于16项研究(N=16 537)。
主要发现
- 与对照相比,ARSI增加骨折风险(RR 2.32,95%CI 2.00-2.71;p<0.01)。
- 与对照相比,ARSI增加跌倒风险(RR 2.22,95%CI 1.81-2.72;p<0.01)。
- 转移性激素敏感性前列腺癌亚组中,骨折风险增加(RR 2.13,95%CI 1.70-2.67;p<0.01),跌倒风险增加(RR 2.19,95%CI 1.53-3.12;p<0.0001)。
- 非转移性前列腺癌亚组中骨折风险增加(RR 2.27,95%CI 1.60-3.20;p<0.00001)。
- 转移性去势抵抗性前列腺癌亚组中骨折风险增加(RR 2.85,95%CI 2.16-3.76;p<0.00001)。
局限性
- 无法区分脆性骨折与病理性骨折。
- 存在竞争风险偏倚的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The addition of androgen receptor signalling inhibitors (ARSIs) to standard androgen deprivation therapy (ADT) has improved survival outcomes in patients with advanced prostate cancer (PCa). Advanced PCa patients have a higher incidence of osteoporosis, compounded by rapid bone density loss upon commencement of ADT resulting in an increased fracture risk. The effect of treatment intensification with ARSIs on fall and fracture risk is unclear. OBJECTIVE: To assess the risk of falls and fractures in men with PCa treated with ARSIs. EVIDENCE ACQUISITION: A systematic review of EMBASE, MEDLINE, The Cochrane Library, and The Health Technology Assessment Database for randomised control trials between 1990 and June 2023 was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analyses guidance. Risk ratios were estimated for the incidence of fracture and fall events. Subgroup analyses by grade of event and disease state were conducted. EVIDENCE SYNTHESIS: Twenty-three studies were eligible for inclusion. Fracture outcomes were reported in 17 studies (N = 18 811) and fall outcomes in 16 studies (N = 16 537). A pooled analysis demonstrated that ARSIs increased the risk of fractures (relative risk [RR] 2.32, 95% confidence interval [CI] 2.00-2.71; p < 0.01) and falls (RR 2.22, 95% CI 1.81-2.72; p < 0.01) compared with control. A subgroup analysis demonstrated an increased risk of both fractures (RR 2.13, 95% CI 1.70-2.67; p < 0.01) and falls (RR 2.19, 95% CI 1.53-3.12; p < 0.0001) in metastatic hormone-sensitive PCa patients, and an increased risk of fractures in the nonmetastatic (RR 2.27, 95% CI 1.60-3.20; p < 0.00001) and metastatic castrate-resistant (RR 2.85, 95% CI 2.16-3.76; p < 0.00001) settings. The key limitations include an inability to distinguish fragility from pathological fractures and potential for a competing risk bias. CONCLUSIONS: Addition of an ARSI to standard ADT significantly increases the risk of fractures and falls in men with prostate cancer. PATIENT SUMMARY: We found a significantly increased risk of both fractures and falls with a combination of novel androgen signalling inhibitors and traditional forms of hormone therapy.
引用
- Jones C, Gray S, Brown M, et al. Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Eur Urol Oncol. 2024. PMID: 38383277. doi:10.1016/j.euo.2024.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。